comparemela.com

Latest Breaking News On - Langcheng capital - Page 1 : comparemela.com

Shunwei backs Ultron Photonics and 13 more deal updates from Greater China

Shunwei backs Ultron Photonics and 13 more deal updates from Greater China
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

China Digest: Dearer nets $65m; Temasek backs Abiochem

China Digest: Dearer nets $65m; Temasek backs Abiochem Dearer nets $65m in Series B Shanghai-headquartered contact lens manufacturer Dearer has raised 420 million yuan ($65 million) in a Series B round of financing.  State-backed alternative asset manager CITIC Private Equity Funds Management (CPE), Legend Holdings’ investment arm Legend Capital and BioTrack Capital joined the round. Insight Capital made a follow-on investment in the round.  The company will use the proceeds for R&D and mass production of coloured contact lenses, the company said in a statement.  Its early-stage investors include Orient Securities, Borchid Capital,  FOF Capital and eyecare service provider Eyebright.  Temasek invests in Abiochem 

China Digest: Bluepha, Youye Technology in funding news

China Digest: Bluepha, Youye Technology in funding news Photo: Pixabay February 26, 2021 Bluepha has secured nearly $200 million yuan ($30 million) in its Series B round of funding co-led by Hillhouse Capital and Lightspeed China Partners. In a separate development, Youye Technology has raised nearly $100 million in a strategic investment. Bluepha nets nearly $30m in Series B  Beijing-headquartered synthetic biology firm Bluepha has secured nearly $200 million yuan ($30 million) in its Series B round of funding co-led by Asia-focused PE firm Hillhouse Capital and early-stage investor Lightspeed China Partners, per a company statement on Friday. The latest round also saw the participation of Chinese apparel conglomerate Septwolves’ investment arm, and Trinity Innovation Fund.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.